Send us Feedback

NPS Pharmaceuticals (NPSP)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
NPS Pharmaceuticals Observes Rare Disease Day 2012
Business Wire  Feb 27  Comment 
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, is joining the National Organization for Rare Disorders (NORD) and other organizations
NPS Pharmaceuticals Reports 2011 Year-End Financial Results and 2012 Cash Burn Guidance
Business Wire  Feb 15  Comment 
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported its 2011 year-end financial results and provided cash burn guidance for
NPS Pharmaceuticals Announces FDA Acceptance of New Drug Application for GATTEX® (teduglutide) for the Treatment of Adult Short Bowel Syndrome (SBS)
Business Wire  Jan 31  Comment 
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced the U.S. Food and Drug Administration (FDA) has accepted and filed for
NPS Pharma (NPSP) announces FDA acceptance of NDA for Gattex(R) in adult SBS
StreetInsider.com  Jan 31  Comment 
NPS Pharma's (NPSP) NDA for GATTEX Accepted by FDA
StreetInsider.com  Jan 31  Comment 
Notable Call Options Activity in NPS Pharmaceuticals
Benzinga  Jan 10  Comment 
Shares of NPS Pharmaceuticals (NASDAQ: NPSP) are higher on the session by 0.27%, currently trading at $6.59. The stock has been moving largely higher over the past two months and is currently trading above the 50-day moving average. Options...
NPS Pharmaceuticals (NPSP) Completes GATTEX NDA Submission to FDA
StreetInsider.com  Dec 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/NPS+Pharmaceuticals+%28NPSP%29+Completes+GATTEX+NDA+Submission+to+FDA/6987147.html for the full story.
Phase III a success for Rare Endocrine Disease Drug. Will Investors Agree?
TheStreet.com  Nov 7  Comment 
NPS Pharmaceuticals CEO Fran�ois Nader tells TheStreet about Natpara, which just successfully completed a phase III. If approved it will be the only drug to treat hypoparathyroidism, a rare endocrine disorder.
Notable Call Options Activity in NPS Pharmaceuticals
Benzinga  Nov 7  Comment 
Shares of NPS Pharmaceuticals (NASDAQ: NPSP) are higher on the session by 1.34%, currently trading at $5.68. The stock has been moving largely lower over the past three months and is currently trading below the 50-day moving average. Options...
NPS Pharma (NPSP) Reports Positive REPLACE Data, Gets Orphan Drug Designation
StreetInsider.com  Nov 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/NPS+Pharma+%28NPSP%29+Reports+Positive+REPLACE+Data%2C+Gets+Orphan+Drug+Designation/6918377.html for the full story.
NPS Pharmaceuticals Shares Plunge 33% on Bowel Drug Deaths
BusinessWeek  Nov 1  Comment 
NPS Pharmaceuticals Inc., a maker of drugs for rare disease, fell 33 percent after saying three people in a study for its experimental Gattex treatment for short bowel syndrome developed cancer and two died.




more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 




References

Retrieved from "http://www.wikinvest.com/stock/NPS_Pharmaceuticals_(NPSP)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki